Strategies to enhance the therapeutic efficacy of antidepressants

Targeting residual symptoms

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is an illness of great morbidity that affects many people across the world. The current goal for treatment of MDD is to achieve remission (i.e., no depressive symptoms). However, despite scientific advances in the treatment for MDD, antidepressants as first-line agents yield only modest remission rates. In fact, a recent study indicated that only one out of three subjects who received a standard, first-line antidepressant attained remission. Not achieving remission from depressive symptoms increases the risk of a more chronic and debilitating course of illness with frequent recurrences. Although a number of reasons contribute to these modest outcomes, the presence of residual symptoms is a major problem. Residual symptoms are defined as symptoms that linger despite an adequate dose and duration of an antidepressant medication. This article reviews the prevalence and clinical impact of common residual symptoms and discusses the utility of aggressively addressing residual symptoms to enhance the efficacy of antidepressant medications.

Original languageEnglish (US)
Pages (from-to)975-984
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume9
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

Antidepressive Agents
Major Depressive Disorder
Depression
Therapeutics
Morbidity
Recurrence

Keywords

  • Antidepressant medication
  • Augmentation strategy
  • Depressive subtype
  • Major depressive disorder
  • Remission
  • Residual symptom

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Strategies to enhance the therapeutic efficacy of antidepressants : Targeting residual symptoms. / Kurian, Benji T.; Greer, Tracy L.; Trivedi, Madhukar H.

In: Expert Review of Neurotherapeutics, Vol. 9, No. 7, 07.2009, p. 975-984.

Research output: Contribution to journalArticle

@article{9167d51fa2874dec92f872138dd9da0e,
title = "Strategies to enhance the therapeutic efficacy of antidepressants: Targeting residual symptoms",
abstract = "Major depressive disorder (MDD) is an illness of great morbidity that affects many people across the world. The current goal for treatment of MDD is to achieve remission (i.e., no depressive symptoms). However, despite scientific advances in the treatment for MDD, antidepressants as first-line agents yield only modest remission rates. In fact, a recent study indicated that only one out of three subjects who received a standard, first-line antidepressant attained remission. Not achieving remission from depressive symptoms increases the risk of a more chronic and debilitating course of illness with frequent recurrences. Although a number of reasons contribute to these modest outcomes, the presence of residual symptoms is a major problem. Residual symptoms are defined as symptoms that linger despite an adequate dose and duration of an antidepressant medication. This article reviews the prevalence and clinical impact of common residual symptoms and discusses the utility of aggressively addressing residual symptoms to enhance the efficacy of antidepressant medications.",
keywords = "Antidepressant medication, Augmentation strategy, Depressive subtype, Major depressive disorder, Remission, Residual symptom",
author = "Kurian, {Benji T.} and Greer, {Tracy L.} and Trivedi, {Madhukar H.}",
year = "2009",
month = "7",
doi = "10.1586/ern.09.53",
language = "English (US)",
volume = "9",
pages = "975--984",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Strategies to enhance the therapeutic efficacy of antidepressants

T2 - Targeting residual symptoms

AU - Kurian, Benji T.

AU - Greer, Tracy L.

AU - Trivedi, Madhukar H.

PY - 2009/7

Y1 - 2009/7

N2 - Major depressive disorder (MDD) is an illness of great morbidity that affects many people across the world. The current goal for treatment of MDD is to achieve remission (i.e., no depressive symptoms). However, despite scientific advances in the treatment for MDD, antidepressants as first-line agents yield only modest remission rates. In fact, a recent study indicated that only one out of three subjects who received a standard, first-line antidepressant attained remission. Not achieving remission from depressive symptoms increases the risk of a more chronic and debilitating course of illness with frequent recurrences. Although a number of reasons contribute to these modest outcomes, the presence of residual symptoms is a major problem. Residual symptoms are defined as symptoms that linger despite an adequate dose and duration of an antidepressant medication. This article reviews the prevalence and clinical impact of common residual symptoms and discusses the utility of aggressively addressing residual symptoms to enhance the efficacy of antidepressant medications.

AB - Major depressive disorder (MDD) is an illness of great morbidity that affects many people across the world. The current goal for treatment of MDD is to achieve remission (i.e., no depressive symptoms). However, despite scientific advances in the treatment for MDD, antidepressants as first-line agents yield only modest remission rates. In fact, a recent study indicated that only one out of three subjects who received a standard, first-line antidepressant attained remission. Not achieving remission from depressive symptoms increases the risk of a more chronic and debilitating course of illness with frequent recurrences. Although a number of reasons contribute to these modest outcomes, the presence of residual symptoms is a major problem. Residual symptoms are defined as symptoms that linger despite an adequate dose and duration of an antidepressant medication. This article reviews the prevalence and clinical impact of common residual symptoms and discusses the utility of aggressively addressing residual symptoms to enhance the efficacy of antidepressant medications.

KW - Antidepressant medication

KW - Augmentation strategy

KW - Depressive subtype

KW - Major depressive disorder

KW - Remission

KW - Residual symptom

UR - http://www.scopus.com/inward/record.url?scp=67651030466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651030466&partnerID=8YFLogxK

U2 - 10.1586/ern.09.53

DO - 10.1586/ern.09.53

M3 - Article

VL - 9

SP - 975

EP - 984

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 7

ER -